Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elotuzumab + lenalidomide + dexamethasone
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Elotuzumab + lenalidomide + dexamethasone is a three-drug combination regimen used for the treatment of multiple myeloma, particularly in patients who have received one to three prior therapies. Elotuzumab is a humanized IgG1 monoclonal antibody that targets the Signaling lymphocyte activation molecule F7 (SLAMF7) protein on myeloma and natural killer (NK) cells, enhancing immune-mediated killing of myeloma cells. Lenalidomide is an immunomodulatory small molecule that exerts anti-myeloma effects through direct tumoricidal activity and immune modulation. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and cytotoxic properties against lymphoid malignancies. The combination has demonstrated improved progression-free survival and overall response rates compared to lenalidomide plus dexamethasone alone in relapsed or refractory multiple myeloma[1][2][6][8].
- Other names
- EloRdE-Ld
02
Targets
CRBN (Cereblon)GR (Glucocorticoid receptor)SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on elotuzumab + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elotuzumab + lenalidomide + dexamethasone.